Xenon downgraded at Deutsche Bank after pause in depression trials

Trial StartnegativeNegative

AI Analysis

Summary

Xenon Pharmaceuticals was downgraded by Deutsche Bank following a pause in its depression trials. The downgrade reflects investor concerns regarding the clinical development program.

Clinical Trial Data

Outcome Details

pause in depression trials

Importance:6/10

Sentiment:

-0.70

clinical trial pausedowngradedepressionnegative catalyst

Related Companies

$XENE

Read the original article

Published by Seeking Alpha Healthcare on September 18, 2026 5:27 PM

Read Original